Bupropion-paroxetine

From Psychiatrienet
Revision as of 15:31, 7 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine

Switch medication from bupropion to paroxetine.[1] [2]

Nietinrijdenbord.png Stop bupropion
  • Before day 1: Gradually reduce dosage of bupropion to a maximum of 150 mg/ day.
  • Day 1: Stop administration of bupropion
Eenrichtingbord.png Start paroxetine
  • Day 2: Start paroxetine in normal dosage of 20 mg/day.
  • After 3 weeks: If necessary increase dosage gradually to 30-50 mg/day.
Infobord.png More information
  • No wash-out period is needed.
  • Bupropion slows the metabolism of paroxetine by CYP2D6.
  • Bupropion and its metabolites have long elimination times, so plasma concentrations will reduce gradually.
  • The interaction by CYP2D6-inhibition is not relevant because of low dosages during the switch.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.